• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Aphena Pharma Solutions

    Almac Group

    Reed-Lane

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Alcami

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers: Hanns-Christian Mahler

    Head of drug product services talks about Lonza’s new capabilities

    Related CONTENT
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • NovalGen and Halix Enter Strategic Partnership
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • Application of ICP-OES/ICP-MS in Pharmaceutical Analysis
    Tim Wright, Editor03.09.16
    Lonza’s pharma and biotech segment recently announced the expansion of its footprint to offer customers a complete portfolio of development and manufacturing services for clinical outsourcing requirements by entering into drug product services.

    These drug product services will focus on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other routes of parenteral administration. Services will include options for monoclonal antibodies, other biologics, drug conjugates, peptides and small molecules that require a parenteral dosage form.

    Drug product services will be offered in the fourth quarter of 2016 from laboratories based in Basel, Switzerland with an initial focus on formulation development and drug product analytical development and quality control. Specialized services will also be available for customers, such as particulate identification, characterization and quantification, excipient and surfactant characterization, extractables and leachables assessment and testing of container closure integrity.

    Heading the drug product business is Prof. Dr. Hanns-Christian Mahler, who for 10 years led the departments of pharmaceutical development and supplies and formulation R&D biologics for Roche. Contract Pharma spoke to Dr. Mahler about Lonza’s move into drug product development services.   —TW


    Contract Pharma: What was the motive for entering the field of Drug Product Development Services?
    Hanns-Christian Mahler:
    Drug Product Services complements Lonza’s current drug substance offerings and enables us to provide one-stop-shop services to our customers. By providing integrated development and manufacturing services of the highest quality, we support our customers in meeting some of the greatest challenges in patient treatment. 

    CP: How will this move facilitate growth and what does it say about the direction your business is headed?
    Mahler:
    The addition of Drug Product Services makes us a fully comprehensive partner by extending our capabilities beyond drug substance. By combining our drug substance and drug product service offerings, we provide our customers a less complex procurement model. This allows rapid and effective progression of their candidates to the clinic and benefits our customers and, ultimately, their patients.

    CP: What is the action plan for integrating this new service offering over the coming years?
    Mahler:
    Drug Product Services will initially focus on formulation development, drug product analytics and quality control. Additional specialized services will also be available including: particle identification (subvisible and submicron), extractables and leachables, and container closure integrity.

    We believe that Drug Product development is an area of significant challenges; and the combined development approach of formulation, drug product processing, primary packaging and integration of the Drug Product/Drug Substance activities will yield a successful product for the patient.

    CP: Why choose parenteral dosage forms as the target area?
    Mahler:
    While oral dosage forms such as tablets or capsules have become a commodity for small molecules, they do offer other areas of challenge, including solubility and permeability that warrant skilled services. Currently, parenteral dosage forms are, and will remain, a major challenge. The more complex molecules such as biologics, next-generation biologics, cell therapy products and other treatment options, require parenteral delivery.

    CP: How would you describe the current state of the market for parenteral dosage development and manufacturing?
    Mahler:
    The market for parenteral dosage forms is fragmented. Some companies focus on fill/finish services while others offer formulation services. A third group offers specialty services such as extractables and leachables or particle identification. In order to address current challenges of parenteral drug product development, we believe that an integrated approach that combines all of these services is the only way to efficiently address the challenges and meet the needs of our customers. This integrated approach delivers accelerated development timelines for early stage clinical testing, process robustness and reliability for commercialization.

    CP: What would you say are three key trends and/or drivers in the contract parenteral dosage business?
    Mahler:
    For one, we are seeing more variable and challenging molecules, along with new formats including more potent molecules (e.g. ADCs) and parenteral product administration moving away from intravenous (IV), towards subcutaneous (SC) or intravitreal (IVT, intraocular) injections. There are specific development challenges with SC and IVT related to stability (e.g. aggregation, particle formation), viscosity (e.g. manufacturability, injectability) and volume to be delivered.

    Second, regulatory expectations are constantly increasing and vary from country to country. Third, more patient-centricity, a stronger focus on safety and convenience and a trend towards self-administration/home use all drive a need for drug/device combination products.

    CP: Where are the opportunities for growth?
    Mahler:
    Given the expertise and experience of our Drug Product Services team, we will be able to provide state-of-the-art services based on strong, industry-based strategies and regulatory experience. Drug Product will be an integrated part of Lonza’s offerings in mammalian, microbial, chemistry, conjugates, cell and viral therapy technologies.

    CP: Conversely, what are the major challenges or obstacles in the market?
    Mahler:
    More potent molecules require smaller doses and ultimately smaller batch sizes. Regulatory expectations are constantly changing and vary from country to country. The fragmented drug product market requires customers to work with several vendors in order to meet regulatory requirements and progress their product to the clinic.

    CP: How are customer expectations evolving?
    Mahler:
    As a drug substance services provider, we have been asked if we offer drug product services. Customers are requesting high quality drug substance/drug product integrated offerings from a provider with a strong focus on people who are handling pharmaceutical drug products, including healthcare providers and patients. Customers also want experienced staff with strong regulatory backgrounds, and state-of-the-art offerings including analytical sciences. Drug product development and drug product design can help to differentiate a product in the market and can support lifecycle management.

    CP: What does the trend towards one-stop-shop service solutions say about the contract development and manufacturing market?
    Mahler:
    One-stop-shop service solutions reduce complexity in supply chain by working with selective strategic partners. Working with one strategic partner from discovery through clinical supply allows a more in-depth knowledge of the product, which supports pharma companies having “clinical value vs. cost” discussions with payers. 


    Tim Wright is editor of Contract Pharma. He can be reached at twright@rodmanmedia.com.
    Related Searches
    • monoclonal antibodies
    • leachables
    • expansion
    • tablets
    Suggested For You
    CatSci Opens New Site in UK CatSci Opens New Site in UK
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    NovalGen and Halix Enter Strategic Partnership NovalGen and Halix Enter Strategic Partnership
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Application of ICP-OES/ICP-MS in Pharmaceutical Analysis Application of ICP-OES/ICP-MS in Pharmaceutical Analysis
    Lonza Expands Solid Small Molecule Services Lonza Expands Solid Small Molecule Services
    BioDuro-Sundia Appoints CEO BioDuro-Sundia Appoints CEO
    Quotient Sciences Acquires Arcinova Quotient Sciences Acquires Arcinova
    Cytiva Acquires Canadian Aseptic Filling Innovator Cytiva Acquires Canadian Aseptic Filling Innovator
    Cytiva Acquires Vanrx Pharmasystems Cytiva Acquires Vanrx Pharmasystems
    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    Humanigen, Emergent Enter Covid-19 Partnership Humanigen, Emergent Enter Covid-19 Partnership
    LSNE Expands Fill Finish and Lyophilization Ops LSNE Expands Fill Finish and Lyophilization Ops
    Drug Product Development, Manufacturing, and Packaging Drug Product Development, Manufacturing, and Packaging
    Irisys Receives NIH Contract for the Formulation of Drinabant Irisys Receives NIH Contract for the Formulation of Drinabant

    Related Features

    • Formulation Development
      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      A strong trend in drug substance and drug product biomanufacturing, as is for formulation, is that of increasing therapeutic complexity.
      Latika Bhonsle-Deeng, Rentschler Biopharma SE, and Konstantin Petropoulos, LEUKOCARE AG 10.14.20

    • Chemistry
      Greener by Design

      Greener by Design

      How new approaches to green chemistry are driving sustainable processes.
      Kenneth Ball, Commercial Operations Lead, Pfizer CentreOne 03.04.20

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18


    • Formulation Development
      Developing Faster-to-Clinic Formulations

      Developing Faster-to-Clinic Formulations

      When standard formulation strategies fail, is there a fast path to clinic for hard-to-formulate therapeutics?
      Phil Morton, Chief Technology Officer, Albumedix 06.12.18

    • Formulation Development
      Formulation Development Trends

      Formulation Development Trends

      Innovation in formulation development continues to be driven by the need to improve drug bioavailability.
      Torkel Gren, General Manager, Recipharm Pharmaceutical Development AB 04.10.18

    • Formulation Development | Preclinical Outsourcing
      Formulating Candidates  with Bioavailability Issues

      Formulating Candidates with Bioavailability Issues

      To avoid the solubility pitfalls that too often halt a medicines progress from clinic to market, it’s vital to start formulat
      Stephen Tindal, Director - Science and Technology, Catalent 05.09.17


    • Drug Development | Formulation Development
      Formulation Strategies for  Aging Consumers

      Formulation Strategies for Aging Consumers

      Convenience, flavor and novel combinations of ingredients can help offer better product experiences.
      Stephen Tindal, Director, Science and Technology, Catalent Pharma Solutions 03.07.17

    • Chemistry | Drug Development
      Know Your Drug:  A Solution to Dissolution

      Know Your Drug: A Solution to Dissolution

      Examining key strategies for solubility and dissolution assessment of new drug products, drug product intermediates and APIs
      Luís Sousa, Mafalda Paiva and Pedro Serôdio, Hovione 03.07.17

    • Drug Development | Formulation Development
      Modeling & Simulation for  Drug Development & Formulation

      Modeling & Simulation for Drug Development & Formulation

      A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.
      Nathan Teuscher and Nikunjkumar Patel , Certara 03.07.17


    • APIs | Clinical Trial Materials | Clinical Trials | Drug Development | Formulation Development
      Choosing Oral Formulations for First-in-man Clinical Trials

      Choosing Oral Formulations for First-in-man Clinical Trials

      Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems
      Jon Sutch, Senior Manager of Formulation Development, Patheon 10.11.16

    • APIs | Chemistry | Cleaning Validation | Clinical Trials | Toxicology | Validation
      Limiting APIs in Manufacturing Effluent

      Limiting APIs in Manufacturing Effluent

      An approach for setting limits on pharmaceuticals discharged in manufacturing effluent
      Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc. 06.02.16

    • Biosimilars | Chemistry | Process Development | Supply Chain
      Biopharma CMO Market Trends

      Biopharma CMO Market Trends

      Continued strong growth in biopharma industry is being driven by biosimilars
      Tim Wright, Editor 06.02.16


    • Biosimilars | Clinical Trials | Formulation Development
      Critical Steps for Biosimilar Assessment

      Critical Steps for Biosimilar Assessment

      Establishing “finger-print like” biosimilarity prior to the clinic
      Fiona Greer, SGS 05.05.16

    • Capsules | Clinical Trials | Excipients | Formulation Development | Serialization
      The Evolution of the ‘One-Stop Shop’  in Clinical Supplies Sourcing

      The Evolution of the ‘One-Stop Shop’ in Clinical Supplies Sourcing

      What does a one-stop shop really mean and is it always best for the client?
      Paul Skultety, Alex McClung, Ted Koontz and Damian Gant, Xcelience, a division of Capsugel Dosage Form Solutions 05.05.16

    • APIs | cGMP Manufacture | Drug Development | Facilities | Formulation Development | Supply Chain

      Newsmakers: Ian Muir

      End-to-End Service
      Tim Wright, Editor 04.05.16

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login